BioMedNewsBreaks — BioAdaptives Inc. (BDPT) Announces Board Appointment of Visionary Leader Mark Frissora

BioAdaptives (OTC: BDPT), a pioneering health and wellness company dedicated to innovative, science-driven solutions, has announced the appointment of Mark Frissora to its board of directors. An acclaimed business leader, Frissora is celebrated for transforming global brands and driving extraordinary growth at Fortune 500 companies such as Hertz and Caesars Entertainment. “Mark’s exceptional track record in revitalizing global brands and his deep expertise in operational excellence make him an invaluable asset,” said James Keener, CEO of BioAdaptives. “His accomplishments speak for themselves, and we are excited to benefit from his insights as we pursue groundbreaking solutions that enhance lives through scientific innovation.”

To view the full press release, visit https://ibn.fm/GjKnU

About BioAdaptives Inc.

BioAdaptives is a leading innovator in the health and wellness industry, dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Its mission is to improve the quality of life for customers by offering products that support optimal health and vitality. For more information about Xcellara(TM) Stem Cell Activator and other BioAdaptives products, visit www.BioAdaptives.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances RTNova Platform with IL15 Superagonist Payload

Calidi Biotherapeutics (NYSE American: CLDI) announced the selection of IL15 superagonist (IL15-IL15Ra) as the first…

11 minutes ago

BioMedNewsBreaks — Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’ 

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical…

3 days ago

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Grants Inducement Stock Option to New CEO Eric Poma

Calidi Biotherapeutics (NYSE American: CLDI) a clinical-stage biotechnology company advancing targeted antitumor virotherapies, announced the…

3 days ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in Benzinga Video Highlighting 75% HyBryte™ Response Rate in FDA-Backed Skin Cancer Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, is featured in a…

3 days ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Partner to Advance Remote ECG Monitoring

HeartBeam (NASDAQ: BEAT), a medical technology firm innovating in personalized cardiac care, has announced a…

4 days ago

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Eric Poma as CEO to Lead Next Phase of Clinical Growth

Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive…

5 days ago